Published in J Cell Sci on June 01, 2000
Xenobiotic, bile acid, and cholesterol transporters: function and regulation. Pharmacol Rev (2010) 2.97
Identification of a missense mutation in the bovine ABCG2 gene with a major effect on the QTL on chromosome 6 affecting milk yield and composition in Holstein cattle. Genome Res (2005) 2.51
Mutations at amino-acid 482 in the ABCG2 gene affect substrate and antagonist specificity. Br J Cancer (2003) 2.33
Mechanisms of chemoresistance in cancer stem cells. Clin Transl Med (2013) 2.20
Lapatinib (Tykerb, GW572016) reverses multidrug resistance in cancer cells by inhibiting the activity of ATP-binding cassette subfamily B member 1 and G member 2. Cancer Res (2008) 2.04
Role of the breast cancer resistance protein (ABCG2) in drug transport. AAPS J (2005) 2.03
The role of the breast cancer resistance protein (ABCG2) in the distribution of sorafenib to the brain. J Pharmacol Exp Ther (2010) 1.59
Increased Nrf2 activation in livers from Keap1-knockdown mice increases expression of cytoprotective genes that detoxify electrophiles more than those that detoxify reactive oxygen species. Toxicol Sci (2009) 1.54
ATP-binding cassette, subfamily G (ABCG family). Pflugers Arch (2006) 1.37
Structure and function of the human breast cancer resistance protein (BCRP/ABCG2). Curr Drug Metab (2010) 1.33
Breast cancer resistance protein (BCRP/ABCG2): its role in multidrug resistance and regulation of its gene expression. Chin J Cancer (2011) 1.30
ABCG2 expression, function, and promoter methylation in human multiple myeloma. Blood (2006) 1.27
Human ABCG2: structure, function, and its role in multidrug resistance. Int J Biochem Mol Biol (2011) 1.21
BCRP/ABCG2 in the placenta: expression, function and regulation. Pharm Res (2008) 1.17
Role of the breast cancer resistance protein (BCRP/ABCG2) in drug transport--an update. AAPS J (2014) 1.17
Nanopreparations to overcome multidrug resistance in cancer. Adv Drug Deliv Rev (2013) 1.14
The mechanism of action of multidrug-resistance-linked P-glycoprotein. J Bioenerg Biomembr (2001) 1.13
Oncogene-specific formation of chemoresistant murine hepatic cancer stem cells. Hepatology (2012) 1.11
Both P-gp and MRP2 mediate transport of Lopinavir, a protease inhibitor. Int J Pharm (2007) 1.10
ABCG transporters: structure, substrate specificities and physiological roles : a brief overview. J Bioenerg Biomembr (2007) 1.09
Stem cell markers: ABCG2 and MCM2 expression in retinoblastoma. Br J Ophthalmol (2006) 1.09
Common variants in ABCB1, ABCC2 and ABCG2 genes and clinical outcomes among women with advanced stage ovarian cancer treated with platinum and taxane-based chemotherapy: a Gynecologic Oncology Group study. Gynecol Oncol (2011) 1.08
ABCG2 transports and transfers heme to albumin through its large extracellular loop. J Biol Chem (2010) 1.06
The role of half-transporters in multidrug resistance. J Bioenerg Biomembr (2001) 1.04
Breast cancer resistance protein (ABCG2) and drug disposition: intestinal expression, polymorphisms and sulfasalazine as an in vivo probe. Pharmacogenet Genomics (2008) 1.03
The emerging pharmacotherapeutic significance of the breast cancer resistance protein (ABCG2). Br J Pharmacol (2007) 1.03
Identification of inhibitors of ABCG2 by a bioluminescence imaging-based high-throughput assay. Cancer Res (2009) 1.02
Hedgehog pathway inhibitor HhAntag691 is a potent inhibitor of ABCG2/BCRP and ABCB1/Pgp. Neoplasia (2009) 1.02
Sensitive and specific fluorescent probes for functional analysis of the three major types of mammalian ABC transporters. PLoS One (2011) 1.01
Enhanced exposure of phosphatidylserine in human gastric carcinoma cells overexpressing the half-size ABC transporter BCRP (ABCG2). Biochem J (2003) 1.01
A functional study on polymorphism of the ATP-binding cassette transporter ABCG2: critical role of arginine-482 in methotrexate transport. Biochem J (2003) 1.00
Rapid detection of ABC transporter interaction: potential utility in pharmacology. J Pharmacol Toxicol Methods (2010) 0.99
Acquired resistance of human T cells to sulfasalazine: stability of the resistant phenotype and sensitivity to non-related DMARDs. Ann Rheum Dis (2004) 0.97
An ATP-binding cassette transporter GhWBC1 from elongating cotton fibers. Plant Physiol (2003) 0.95
Repositioning of Tyrosine Kinase Inhibitors as Antagonists of ATP-Binding Cassette Transporters in Anticancer Drug Resistance. Cancers (Basel) (2014) 0.95
Nanoscale drug delivery systems and the blood-brain barrier. Int J Nanomedicine (2014) 0.94
Interleukin-1 beta and tumor necrosis factor-alpha increase ABCG2 expression in MCF-7 breast carcinoma cell line and its mitoxantrone-resistant derivative, MCF-7/MX. Inflamm Res (2009) 0.94
Motesanib (AMG706), a potent multikinase inhibitor, antagonizes multidrug resistance by inhibiting the efflux activity of the ABCB1. Biochem Pharmacol (2014) 0.93
mRNA expression profile of multidrug-resistant genes in acute lymphoblastic leukemia of children, a prognostic value for ABCA3 and ABCA2. Cancer Biol Ther (2013) 0.93
Mitoxantrone resistance in a small cell lung cancer cell line is associated with ABCA2 upregulation. Br J Cancer (2004) 0.92
Inhibition of placental P-glycoprotein: impact on indinavir transfer to the foetus. Br J Clin Pharmacol (2007) 0.92
Heterogeneity in the rat brain vasculature revealed by quantitative confocal analysis of endothelial barrier antigen and P-glycoprotein expression. J Cereb Blood Flow Metab (2011) 0.90
Challenges in the development of future treatments for breast cancer stem cells. Breast Cancer (Dove Med Press) (2010) 0.89
Gene and functional up-regulation of the BCRP/ABCG2 transporter in hepatocellular carcinoma. BMC Gastroenterol (2012) 0.89
Masitinib antagonizes ATP-binding cassette subfamily G member 2-mediated multidrug resistance. Int J Oncol (2014) 0.89
Efficacy of novel P-glycoprotein inhibitors to increase the oral uptake of paclitaxel in mice. Invest New Drugs (2004) 0.89
Clinico-pathologic function of cerebral ABC transporters - implications for the pathogenesis of Alzheimer's disease. Curr Alzheimer Res (2008) 0.88
Synthesis and characterization of a BODIPY conjugate of the BCR-ABL kinase inhibitor Tasigna (nilotinib): evidence for transport of Tasigna and its fluorescent derivative by ABC drug transporters. Mol Pharm (2011) 0.88
Multidrug transporter activity in lymphocytes. Br J Pharmacol (2004) 0.88
The multidrug transporter ABCG2 (BCRP) is inhibited by plant-derived cannabinoids. Br J Pharmacol (2007) 0.87
Axitinib targeted cancer stemlike cells to enhance efficacy of chemotherapeutic drugs via inhibiting the drug transport function of ABCG2. Mol Med (2012) 0.87
Sensitization of ABCB1 overexpressing cells to chemotherapeutic agents by FG020326 via binding to ABCB1 and inhibiting its function. Biochem Pharmacol (2009) 0.85
Localization and substrate selectivity of sea urchin multidrug (MDR) efflux transporters. J Biol Chem (2012) 0.85
A comparative small-animal PET evaluation of [11C]tariquidar, [11C]elacridar and (R)-[11C]verapamil for detection of P-glycoprotein-expressing murine breast cancer. Eur J Nucl Med Mol Imaging (2011) 0.84
Cigarette smoke promotes drug resistance and expansion of cancer stem cell-like side population. PLoS One (2012) 0.84
Structuring detergents for extracting and stabilizing functional membrane proteins. PLoS One (2011) 0.82
Transmembrane helices 1 and 6 of the human breast cancer resistance protein (BCRP/ABCG2): identification of polar residues important for drug transport. Am J Physiol Cell Physiol (2010) 0.82
Transport in technicolor: mapping ATP-binding cassette transporters in sea urchin embryos. Mol Reprod Dev (2014) 0.81
Hydrogen-bond formation of the residue in H-loop of the nucleotide binding domain 2 with the ATP in this site and/or other residues of multidrug resistance protein MRP1 plays a crucial role during ATP-dependent solute transport. Biochim Biophys Acta (2006) 0.81
Berry anthocyanins and anthocyanidins exhibit distinct affinities for the efflux transporters BCRP and MDR1. Br J Pharmacol (2009) 0.81
Computational analysis and predictive modeling of polymorph descriptors. Chem Cent J (2013) 0.81
Retinoblastoma major review with updates on Middle East management protocols. Saudi J Ophthalmol (2012) 0.81
Evaluation of (64)Cu(DO3A-xy-TPEP) as a potential PET radiotracer for monitoring tumor multidrug resistance. Bioconjug Chem (2009) 0.80
Expression Profile of Drug and Nutrient Absorption Related Genes in Madin-Darby Canine Kidney (MDCK) Cells Grown under Differentiation Conditions. Pharmaceutics (2012) 0.79
Effects of α-adrenoceptor antagonists on ABCG2/BCRP-mediated resistance and transport. PLoS One (2012) 0.79
Structure-activity relationships of tariquidar analogs as multidrug resistance modulators. AAPS J (2009) 0.79
Identification and functional characterization of breast cancer resistance protein in human bronchial epithelial cells (Calu-3). Int J Pharm (2009) 0.79
Intestinal expression of mouse Abcg2/breast cancer resistance protein (BCRP) gene is under control of circadian clock-activating transcription factor-4 pathway. J Biol Chem (2012) 0.79
Sequence mutations of the substrate binding pocket of stem cell factor and multidrug resistance protein ABCG2 in renal cell cancer: a possible link to treatment resistance. Oncol Rep (2013) 0.78
Interaction of Isoflavones with the BCRP/ABCG2 Drug Transporter. Curr Drug Metab (2015) 0.78
ABCG2-overexpressing S1-M1-80 cell xenografts in nude mice keep original biochemistry and cell biological properties. Chin J Cancer (2012) 0.78
Dynamic assessment of mitoxantrone resistance and modulation of multidrug resistance by valspodar (PSC833) in multidrug resistance human cancer cells. J Pharmacol Exp Ther (2009) 0.78
Recapitulation of complex transport and action of drugs at the tumor microenvironment using tumor-microenvironment-on-chip. Cancer Lett (2015) 0.78
Differential expression of stem cell markers and vascular endothelial growth factor in human retinoblastoma tissue. Korean J Ophthalmol (2010) 0.77
Jump into a New Fold-A Homology Based Model for the ABCG2/BCRP Multidrug Transporter. PLoS One (2016) 0.75
SOX4 contributes to the progression of cervical cancer and the resistance to the chemotherapeutic drug through ABCG2. Cell Death Dis (2015) 0.75
Kinetic Modeling of ABCG2 Transporter Heterogeneity: A Quantitative, Single-Cell Analysis of the Side Population Assay. PLoS Comput Biol (2016) 0.75
Molecular pathology of retinoblastoma. Middle East Afr J Ophthalmol (2010) 0.75
Functional diversification of sea urchin ABCC1 (MRP1) by alternative splicing. Am J Physiol Cell Physiol (2016) 0.75
Low-density lipoprotein-coupled micelles with reduction and pH dual sensitivity for intelligent co-delivery of paclitaxel and siRNA to breast tumor. Int J Nanomedicine (2017) 0.75
Extracellular concentration of anticancer drugs that regulates their intracellular distribution and binding to DNA in cells with multidrug resistant phenotype. Dokl Biochem Biophys (2007) 0.75
An information-intensive approach to the molecular pharmacology of cancer. Science (1997) 11.43
MD-2, a molecule that confers lipopolysaccharide responsiveness on Toll-like receptor 4. J Exp Med (1999) 9.23
A multidrug resistance transporter from human MCF-7 breast cancer cells. Proc Natl Acad Sci U S A (1998) 6.47
The development of close relationships in Japan and the United States: paths of symbiotic harmony and generative tension. Child Dev (2001) 4.96
Cutting edge: endotoxin tolerance in mouse peritoneal macrophages correlates with down-regulation of surface toll-like receptor 4 expression. J Immunol (2000) 4.10
Direct interaction of microtubule- and actin-based transport motors. Nature (1999) 3.25
Cutting edge: cell surface expression and lipopolysaccharide signaling via the toll-like receptor 4-MD-2 complex on mouse peritoneal macrophages. J Immunol (2000) 3.10
Helicobacter pylori urease activity is toxic to human gastric epithelial cells. Infect Immun (1990) 3.01
Molecular cloning of cDNAs which are highly overexpressed in mitoxantrone-resistant cells: demonstration of homology to ABC transport genes. Cancer Res (1999) 2.70
Developmental defects of lymphoid cells in Jak3 kinase-deficient mice. Immunity (1995) 2.70
The borderline cervical smear. Cytopathology (1995) 2.60
The use and abuse of population viability analysis. Trends Ecol Evol (2001) 2.40
Invasiveness and metastasis of NIH 3T3 cells induced by Met-hepatocyte growth factor/scatter factor autocrine stimulation. Proc Natl Acad Sci U S A (1994) 2.36
Mutations at amino-acid 482 in the ABCG2 gene affect substrate and antagonist specificity. Br J Cancer (2003) 2.33
Requirement of atypical protein kinase clambda for insulin stimulation of glucose uptake but not for Akt activation in 3T3-L1 adipocytes. Mol Cell Biol (1998) 2.32
The hyaluronate receptor is a member of the CD44 (H-CAM) family of cell surface glycoproteins. J Cell Biol (1990) 2.32
Fumitremorgin C reverses multidrug resistance in cells transfected with the breast cancer resistance protein. Cancer Res (2000) 2.32
Requirements for hyaluronic acid binding by CD44: a role for the cytoplasmic domain and activation by antibody. J Exp Med (1992) 2.30
Met and hepatocyte growth factor/scatter factor expression in human gliomas. Cancer Res (1997) 2.30
Overexpression of the ATP-binding cassette half-transporter, ABCG2 (Mxr/BCrp/ABCP1), in flavopiridol-resistant human breast cancer cells. Clin Cancer Res (2001) 2.25
Inhibitor of histone deacetylation, depsipeptide (FR901228), in the treatment of peripheral and cutaneous T-cell lymphoma: a case report. Blood (2001) 2.25
Colposcopic assessment of the accuracy of cervical cytology screening. Br Med J (Clin Res Ed) (1988) 2.22
Toll-like receptor 4, but not toll-like receptor 2, is a signaling receptor for Escherichia and Salmonella lipopolysaccharides. J Immunol (2000) 2.16
Thyroid gland abnormalities in patients with the syndrome of spotty skin pigmentation, myxomas, endocrine overactivity, and schwannomas (Carney complex) J Clin Endocrinol Metab (1997) 2.14
MD-2 enables Toll-like receptor 2 (TLR2)-mediated responses to lipopolysaccharide and enhances TLR2-mediated responses to Gram-positive and Gram-negative bacteria and their cell wall components. J Immunol (2001) 2.12
The met proto-oncogene receptor and lumen formation. Science (1992) 2.08
Plasmodium falciparum and Plasmodium coatneyi: immunogenicity of "knob-like protrusions" on infected erythrocyte membranes. Exp Parasitol (1977) 2.07
Large plasma membrane disruptions are rapidly resealed by Ca2+-dependent vesicle-vesicle fusion events. J Cell Biol (1997) 2.01
B lymphocytes differentially use the Rel and nuclear factor kappaB1 (NF-kappaB1) transcription factors to regulate cell cycle progression and apoptosis in quiescent and mitogen-activated cells. J Exp Med (1998) 2.00
Real-space observation of current-driven domain wall motion in submicron magnetic wires. Phys Rev Lett (2004) 1.99
Patching plasma membrane disruptions with cytoplasmic membrane. J Cell Sci (2000) 1.96
Molecular genetic analysis of an endotoxin nonresponder mutant cell line: a point mutation in a conserved region of MD-2 abolishes endotoxin-induced signaling. J Exp Med (2001) 1.95
Contraction-induced cell wounding and release of fibroblast growth factor in heart. Circ Res (1995) 1.94
Lipopolysaccharide induces physical proximity between CD14 and toll-like receptor 4 (TLR4) prior to nuclear translocation of NF-kappa B. J Immunol (2000) 1.94
Differential expression and responsiveness of chemokine receptors (CXCR1-3) by human microvascular endothelial cells and umbilical vein endothelial cells. FASEB J (2000) 1.93
From MDR to MXR: new understanding of multidrug resistance systems, their properties and clinical significance. Cell Mol Life Sci (2001) 1.89
Establishment and characterization of SV40 T-antigen immortalized human esophageal epithelial cells. Cancer Res (1991) 1.88
Use of the polymerase chain reaction in the quantitation of mdr-1 gene expression. Biochemistry (1990) 1.83
Methods to detect P-glycoprotein-associated multidrug resistance in patients' tumors: consensus recommendations. Cancer Res (1996) 1.82
Activation of human T lymphocytes is inhibited by peroxisome proliferator-activated receptor gamma (PPARgamma) agonists. PPARgamma co-association with transcription factor NFAT. J Biol Chem (2000) 1.82
A functional assay for detection of the mitoxantrone resistance protein, MXR (ABCG2). Biochim Biophys Acta (2001) 1.82
Acquired mutations in the MXR/BCRP/ABCP gene alter substrate specificity in MXR/BCRP/ABCP-overexpressing cells. Cancer Res (2001) 1.81
Sulphasalazine and male infertility: reversibility and possible mechanism. Gut (1981) 1.80
The Met proto-oncogene mesenchymal to epithelial cell conversion. Science (1994) 1.77
Activation of toll-like receptor 2 on human dendritic cells triggers induction of IL-12, but not IL-10. J Immunol (2000) 1.77
The inducibly expressed GTPase localizes to the endoplasmic reticulum, independently of GTP binding. J Biol Chem (1997) 1.75
The toll-like receptor protein RP105 regulates lipopolysaccharide signaling in B cells. J Exp Med (2000) 1.71
Rhodamine efflux patterns predict P-glycoprotein substrates in the National Cancer Institute drug screen. Mol Pharmacol (1994) 1.70
Establishing a community network for recruitment of African Americans into a clinical trial. The African-American antiplatelet stroke Prevention Study (AAASPS) experience. J Natl Med Assoc (1996) 1.68
Loss of heterozygosity involves multiple tumor suppressor genes in human esophageal cancers. Cancer Res (1992) 1.65
Mouse toll-like receptor 4.MD-2 complex mediates lipopolysaccharide-mimetic signal transduction by Taxol. J Biol Chem (2000) 1.65
Heterogeneous expression of melanoma-associated antigens and HLA-A2 in metastatic melanoma in vivo. Int J Cancer (1998) 1.65
Camptothecin resistance: role of the ATP-binding cassette (ABC), mitoxantrone-resistance half-transporter (MXR), and potential for glucuronidation in MXR-expressing cells. Cancer Res (1999) 1.62
Reduction to homozygosity involving p53 in esophageal cancers demonstrated by the polymerase chain reaction. Proc Natl Acad Sci U S A (1991) 1.62
Pancreatic insufficiency and neutropenia with associated immunoglobulin deficit. Arch Intern Med (1970) 1.61
P21-dependent g(1)arrest with downregulation of cyclin D1 and upregulation of cyclin E by the histone deacetylase inhibitor FR901228. Br J Cancer (2000) 1.60
Primary structure of AfsR, a global regulatory protein for secondary metabolite formation in Streptomyces coelicolor A3(2). Gene (1990) 1.57
A possible correlation between the type of bcr-abl hybrid messenger RNA and platelet count in Philadelphia-positive chronic myelogenous leukemia. Blood (1991) 1.56
Loss of heterozygosity involving the APC and MCC genetic loci occurs in the majority of human esophageal cancers. Proc Natl Acad Sci U S A (1992) 1.56
Paclitaxel chemotherapy after autologous stem-cell transplantation and engraftment of hematopoietic cells transduced with a retrovirus containing the multidrug resistance complementary DNA (MDR1) in metastatic breast cancer patients. Clin Cancer Res (1999) 1.54
Imatinib mesylate and nilotinib (AMN107) exhibit high-affinity interaction with ABCG2 on primitive hematopoietic stem cells. Leukemia (2007) 1.52
Reversal of resistance by GF120918 in cell lines expressing the ABC half-transporter, MXR. Cancer Lett (1999) 1.52
Met expression and sarcoma tumorigenicity. Cancer Res (1993) 1.50
Nonenzymatic glycosylation of hemoglobin. J Biol Chem (1977) 1.49
Human MD-2 confers on mouse Toll-like receptor 4 species-specific lipopolysaccharide recognition. Int Immunol (2001) 1.49
Microsatellite instability occurs frequently and in both diploid and aneuploid cell populations of Barrett's-associated esophageal adenocarcinomas. Cancer Res (1994) 1.49
Opiates transdeactivate chemokine receptors: delta and mu opiate receptor-mediated heterologous desensitization. J Exp Med (1998) 1.48
The HER tyrosine kinase inhibitor CI1033 enhances cytotoxicity of 7-ethyl-10-hydroxycamptothecin and topotecan by inhibiting breast cancer resistance protein-mediated drug efflux. Cancer Res (2001) 1.45
Characterization of estrogen responsive transforming activity in human breast cancer cell lines. Cancer Res (1986) 1.44
Increased incidence of follicular lymphoma in the duodenum. Am J Surg Pathol (2000) 1.42
Cyclooxygenase metabolism of endogenous arachidonic acid by cultured human tracheal epithelial cells. Am Rev Respir Dis (1989) 1.41
Small cell lung cancer treated in southeast Wales. Clin Oncol (R Coll Radiol) (2006) 1.40
Promoter characterization and genomic organization of the human breast cancer resistance protein (ATP-binding cassette transporter G2) gene. Biochim Biophys Acta (2001) 1.40
Archival analysis of p53 genetic and protein alterations in Chinese esophageal cancer. Oncogene (1991) 1.40
Response of the human neurogenic bladder to KCl, carbachol, ATP and CaCl2. Br J Urol (1993) 1.39
Breast cancer resistance protein directly confers SN-38 resistance of lung cancer cells. Biochem Biophys Res Commun (2001) 1.39
Effect of varicocelectomy on sperm parameters and pregnancy rate in patients with subclinical varicocele: a randomized prospective controlled study. J Urol (1996) 1.39
Successful use of interferon for male infertility. Lancet (1994) 1.38
A short-term eradication therapy for Helicobacter pylori acute gastritis. J Gastroenterol Hepatol (2000) 1.38
Immune selection after antigen-specific immunotherapy of melanoma. Surgery (1999) 1.34
PBK/TOPK is a novel mitotic kinase which is upregulated in Burkitt's lymphoma and other highly proliferative malignant cells. Blood Cells Mol Dis (2002) 1.34
Toll-like receptors confer responsiveness to lipopolysaccharide from Porphyromonas gingivalis in human gingival fibroblasts. Infect Immun (2000) 1.33
Molecular characterization of type-specific capsular polysaccharide biosynthesis genes of Streptococcus agalactiae type Ia. J Bacteriol (1999) 1.32
Monoclonal antibodies to CD44 and their influence on hyaluronan recognition. J Cell Biol (1995) 1.31
RP105 is associated with MD-1 and transmits an activation signal in human B cells. Blood (1998) 1.29
Adherence of Helicobacter pylori to cultured human gastric epithelial cells. Infect Immun (1993) 1.28
Single-step doxorubicin-selected cancer cells overexpress the ABCG2 drug transporter through epigenetic changes. Br J Cancer (2008) 1.27
Tumorigenesis induced by coexpression of human hepatocyte growth factor and the human met protooncogene leads to high levels of expression of the ligand and receptor. Cell Growth Differ (1993) 1.27
Immunological skin testing and interpretation: a plea for uniformity. Cancer (1979) 1.26
Immunocytochemistry in effusion cytology: a contemporary review. Cancer (2001) 1.25
An amplification of IL-10 and TGF-beta in patients with IgG4-related tubulointerstitial nephritis. Clin Nephrol (2010) 1.24
IL-5 induces a Pgp-1 (CD44) bright B cell subpopulation that is highly enriched in proliferative and Ig secretory activity and binds to hyaluronate. J Immunol (1990) 1.24